RACHELLE DOODY to Antiparkinson Agents
This is a "connection" page, showing publications RACHELLE DOODY has written about Antiparkinson Agents.
Connection Strength
0.720
-
Refining treatment guidelines in Alzheimer's disease. Geriatrics. 2005 Jun; Suppl:14-20.
Score: 0.238
-
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data. Parkinsonism Relat Disord. 2025 Mar; 132:107257.
Score: 0.231
-
Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022 08 04; 387(5):421-432.
Score: 0.196
-
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Nat Med. 2024 Apr; 30(4):1096-1103.
Score: 0.055